Aug 9 (Reuters) - Merck & Co Inc ( MRK ):
* MERCK TO ACQUIRE INVESTIGATIONAL B-CELL DEPLETION THERAPY,
CN201, FROM CURON BIOPHARMACEUTICAL
* MERCK & CO INC ( MRK ) - PAYS $700M UPFRONT FOR CN201
* MERCK & CO INC ( MRK ) - CURON ELIGIBLE FOR $600M MILESTONE
PAYMENTS
* MERCK & CO INC ( MRK ) - EXPECTS TO RECORD A PRE-TAX CHARGE OF
APPROXIMATELY $750 MILLION
* MERCK & CO INC ( MRK ) - TO UPDATE FINANCIAL OUTLOOK IN Q3 2024
Source text for Eikon:
Further company coverage: